PDS Biotech's Versamune® HPV Shows Promising Results in Head and Neck Cancer Trial
核心洞察
Updated data from the VERSATILE-002 trial shows Versamune® HPV (搜索) combined with pembrolizumab demonstrates a median overall survival of 30 months in HPV16 (搜索)-positive recurrent/metastatic HNSCC patients.
The combination therapy achieved an objective response rate of 36% and a disease control rate of 77% in the first-line treatment of HNSCC.
A significant 21% of patients experienced deep tumor responses with 90-100% tumor shrinkage, highlighting the potential for substantial clinical benefit.
PDS Biotechnology Corporation announced updated results from its VERSATILE-002 Phase 2 clinical trial, revealing promising outcomes for Versamune® HPV (搜索) (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for patients with HPV16 (搜索)-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (搜索) (HNSCC). The data, presented at the European Society for Medical Oncology (ESMO) Congress 2024, indicate a significant improvement in survival and response rates compared to historical data with pembrolizumab alone.
Key Findings from VERSATILE-002
The VERSATILE-002 trial, a single-arm Phase 2 study, enrolled 53 patients with HPV16 (搜索)-positive R/M HNSCC. As of the data cut on May 17, 2024, the combination of Versamune® HPV (搜索) and pembrolizumab demonstrated:
- Median Overall Survival (mOS): 30 months (95% CI: 19.7 months to not reached), compared to 12-18 months historically observed with pembrolizumab.
- Objective Response Rate (ORR): 36% (19/53 patients), versus 19-25% with pembrolizumab alone.
- Disease Control Rate (DCR): 77% (41/53 patients).
- Deep Tumor Responses: 21% (11/53 patients) experienced 90-100% tumor shrinkage.
- Complete Response Rate: 9% (5/53 patients).
These results suggest a clinically meaningful benefit for patients with HPV16 (搜索)-positive HNSCC, a population with significant unmet medical needs. The treatment-related adverse events of Grade ≥3 were observed in 9 patients (Grade 3, n=8 and Grade 4, n=1), indicating manageable tolerability.
Expert Commentary
"The updated response data we presented at ESMO show the strong clinical activity and durability of Versamune® HPV (搜索) plus pembrolizumab," said Dr. Jared Weiss, Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at the University of North Carolina, and principal investigator of the VERSATILE-002 clinical trial. "Continued evaluation shows the promise of this combination in improving survival for patients with HPV16 (搜索)-positive HNSCC."
VERSATILE-003: A Phase 3 Trial on the Horizon
Building on these encouraging Phase 2 results, PDS Biotech (搜索) is planning to initiate the VERSATILE-003, a global, randomized, controlled Phase 3 clinical trial. This trial will evaluate Versamune® HPV (搜索) plus pembrolizumab versus pembrolizumab monotherapy as a first-line treatment in patients with HPV16 (搜索)-positive R/M HNSCC with CPS ≥1.
Implications for HNSCC Treatment
Head and neck squamous cell carcinoma (搜索) is a challenging disease, and HPV16 (搜索)-positive tumors represent a distinct and growing subset. The current standard of care, pembrolizumab, offers limited survival benefits, highlighting the need for more effective therapies. Versamune® HPV (搜索), with its unique mechanism of action, has the potential to address this unmet need by enhancing the immune response against HPV16-positive cancer cells.
"We’re encouraged to see that as the data from our VERSATILE-002 clinical trial have matured, responses continue to improve, suggesting durability of the Versamune® HPV (搜索) induced anti-tumor immune response," said Dr. Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech (搜索). "The encouraging patient survival and clinical responses coupled with promising tolerability as seen in the VERSATILE-002 trial underscore our belief in the potential of the combination to be the first HPV-targeted immunotherapy for HNSCC, and a significant advancement in the treatment of the growing population of patients with HPV16 (搜索)-positive HNSCC. We are working toward initiating the VERSATILE-003 Phase 3 study this year."